304 related articles for article (PubMed ID: 30469048)
1. Paclitaxel-betulinic acid hybrid nanosuspensions for enhanced anti-breast cancer activity.
Wang R; Yang M; Li G; Wang X; Zhang Z; Qiao H; Chen J; Chen Z; Cui X; Li J
Colloids Surf B Biointerfaces; 2019 Feb; 174():270-279. PubMed ID: 30469048
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of betulinic acid on MCF-7 tumors in nude mice.
Damle AA; Pawar YP; Narkar AA
Indian J Exp Biol; 2013 Jul; 51(7):485-91. PubMed ID: 23898546
[TBL] [Abstract][Full Text] [Related]
3. Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78.
Cai Y; Zheng Y; Gu J; Wang S; Wang N; Yang B; Zhang F; Wang D; Fu W; Wang Z
Cell Death Dis; 2018 May; 9(6):636. PubMed ID: 29802332
[TBL] [Abstract][Full Text] [Related]
4. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.
Chowdhury P; Nagesh PKB; Hatami E; Wagh S; Dan N; Tripathi MK; Khan S; Hafeez BB; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
J Colloid Interface Sci; 2019 Feb; 535():133-148. PubMed ID: 30292104
[TBL] [Abstract][Full Text] [Related]
5. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.
Diab T; Alkafaas SS; Shalaby TI; Hessien M
Anticancer Agents Med Chem; 2020; 20(13):1582-1591. PubMed ID: 32364081
[TBL] [Abstract][Full Text] [Related]
7. Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer.
Chen SH; Liu TI; Chuang CL; Chen HH; Chiang WH; Chiu HC
J Mater Chem B; 2020 May; 8(17):3789-3800. PubMed ID: 32150202
[TBL] [Abstract][Full Text] [Related]
8. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.
Li L; Yang M; Li R; Hu J; Yu L; Qian X
Anticancer Agents Med Chem; 2021; 21(7):910-918. PubMed ID: 32698755
[TBL] [Abstract][Full Text] [Related]
9. Enhancing Betulinic Acid Dissolution Rate and Improving Antitumor Activity via Nanosuspension Constructed by Anti-Solvent Technique.
Li S; Zhang J; Fang Y; Yi J; Lu Z; Chen Y; Guo B
Drug Des Devel Ther; 2020; 14():243-256. PubMed ID: 32021108
[TBL] [Abstract][Full Text] [Related]
10. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
11. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
12. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
[TBL] [Abstract][Full Text] [Related]
13. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy.
Ruttala HB; Ko YT
Pharm Res; 2015 Mar; 32(3):1002-16. PubMed ID: 25213777
[TBL] [Abstract][Full Text] [Related]
14. Impacts of particle size on the cytotoxicity, cellular internalization, pharmacokinetics and biodistribution of betulinic acid nanosuspensions in combined chemotherapy.
Wang R; Wang X; Jia X; Wang H; Li W; Li J
Int J Pharm; 2020 Oct; 588():119799. PubMed ID: 32828973
[TBL] [Abstract][Full Text] [Related]
15. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2017 Dec; 40(12):1420-1432. PubMed ID: 29027133
[TBL] [Abstract][Full Text] [Related]
16. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
[TBL] [Abstract][Full Text] [Related]
17. Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.
Cao Y; Wei Z; Li M; Wang H; Yin L; Chen D; Wang Y; Chen Y; Yuan Q; Pu X; Zong L; Duan S
Curr Cancer Drug Targets; 2019; 19(4):338-347. PubMed ID: 29956630
[TBL] [Abstract][Full Text] [Related]
18. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel.
Li J; Yin T; Wang L; Yin L; Zhou J; Huo M
Int J Pharm; 2015 Apr; 483(1-2):38-48. PubMed ID: 25655715
[TBL] [Abstract][Full Text] [Related]
19. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
